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The present study was planned to investigate the disposition kinetics of levoﬂoxacin in plasma of female native Barky breed sheep
aftersingleintravenous(IV)andintramuscular(IM)administrationof4mg/kgbodyweight.Theconcentrationsoflevoﬂoxacinin
the plasma were measured using high-performance liquid chromatography (HPLC) with a UV detector on samples collected at 0,
0.08, 0.16, 0.33, 0.5, 1, 2, 4, 6, 8, 10, 12, 18, 24, 32, and 48h after treatment. Following intravenous injection, the decline in plasma
drug concentration was biexponential with half-lives of (t1/2α)0.33±0.12h and (t1/2β)3.29±0.23h for distribution and elimination
phases, respectively. The volume of distribution at steady state V(d(ss)) was 0.86 ± 0.23l/kg. After intramuscular administration
of levoﬂoxacin at the same dose, the peak plasma concentration (Cmax)w a s3 .1 ± 0.35μg/mL and was obtained at 1.64 ± 0.29h
(Tmax), the elimination half-life (T1/2el)w a s3 .58 ± 0.30h, and AUC was 20.24 ± 1.31μg.h/mL. The systemic bioavailability was
91.35 ± 6.81%. In vitro plasma protein binding was 23.74%. When approved therapy fails, levoﬂoxacin may be used in some
countries for therapy of food animals, however, that is not true in the US.
1.Introduction
Levoﬂoxacin is a recently introduced third-generation ﬂuo-
roquinolones with high activity against a wide spectrum of
Gram-positive and Gram-negative bacteria [1]. In human
clinical trials, levoﬂoxacin has been found to be very
eﬀective in the treatment of infections of upper and lower
respiratory tract, genitourinary system, and skin and soft
tissue [2]. Compared to other ﬂuoroquinolones, oﬂoxacin
and ciproﬂoxacin, levoﬂoxacin has more pronounced bacte-
ricidal activity against organisms such as Pseudomonas and
Enterobacteriaceae [3]. The bactericidal eﬀect of levoﬂoxacin
is achieved through reversible binding to DNA gyrase and
subsequentinhibition of bacterial DNA replication and tran-
scription [4–6]. Fluoroquinolones act by a concentration-
dependent killing mechanism, whereby the optimal eﬀect is
attained by the administration of high doses over a short
period of time [7]. This concentration-dependent killing
proﬁleisassociatedwitharelativelyprolongedpostantibiotic
eﬀect [8]. For this class of antimicrobials, drug exposure, as
measured by the area under the plasma concentration versus
time curve (AUC), has been used to calculate surrogate
eﬃcacy indices, such as the AUC/MIC ratio, where MIC
stands for the in vitro minimal inhibiting concentration of
the tested bacteria [9–11]. Thus, variations of drug exposure
can be associated with variations in the probability of a
successful outcome with a speciﬁc dosage regime.
The drug undergoes a limited metabolism in rats and
human [12] and is primarily excreted by kidney mainly as
active drug. Inactive metabolites (N-oxide and desmethyl
metabolites) represent <5% of the total dose [13], as other
ﬂuoroquinolones are metabolised in chickens as reported
in [14–16], as chickens metabolized marboﬂoxacin to N-
desmethyl-marboﬂoxacin.
The pharmacokinetics of levoﬂoxacin has been investi-
gated in a limited number of animal species including rats
[17], rabbits [18], calves [19, 20], goats [21], cats [22], male
camels[23],and stallions [24].However, there is noavailable
information on the kinetics of levoﬂoxacin in the sheep.
Therefore, the present study was undertaken to determine2 Veterinary Medicine International
the disposition kinetics and bioavailability of levoﬂoxacin in
sheep following a single intravenous (IV) or intramuscular
(IM) administration of 4mg/kg bwt.
2.MaterialandMethods
2.1. Drugs and Chemicals. Levaquin (25mg/mL of levoﬂo-
xacin solution) was obtained from Janssen Pharmaceutica N
V (Beerse, Belgium). Ciproﬂoxacin as internal standard was
purchased from Sigma, Chemical Company (St. Louis, MO,
USA). The solvents (Baker Inc., Phillipsburg, NJ, USA) used
during the chromatographic analysis of the drug were HPLC
grade.
2.2. Experimental Animals. The study was approved by the
Animal Care and Use Committee at the Faculty of Veterinary
Medicine, Cairo University. We used ten female native Barky
breed 2-3 years old, 45–55kg body weight. The animals were
inoptimalnutritionalcondition,fedonconcentratedpellets,
hay, and alfalfa, and had free access to water ad libitum
daily. The health of all animals was monitored prior to and
throughout the experimental period.
2.3. Drug Administration. The study was performed in two
phases, following a crossover design (5 × 5). Animals were
randomly assigned into two groups, with each group con-
taining ﬁve animals. In phase one of the study, ﬁve animals
were given a single intravenous injection into the left jugular
vein at dose of 4mg/kg bodyweight levoﬂoxacin, and the
other ﬁve were injected intramuscularly into the lower third
region of the neck muscles with the drug at the same dose.
Three ml venous whole blood samples were taken by jugular
venepuncture into 10mL heparinized Vacutainers (Becton
Dickinson vacutainer Systems, Rutherford, NJ, USA). The
sampling times were 0 (blank sample), 0.08, 0.16, 0.33, 0.5,
1, 2, 4, 6, 8, 10, 12, 18, 24, 32, and 48h after treatment.
All the blood samples were centrifuged at 3000g for 15min
to separate the plasma. The plasma samples were frozen at
−20
◦C until analysed. After a washout period of 2weeks, the
animals that had been injected intravenously with the drug
were injected intramuscularly and vice versa. Pilot studies
have shown that a 2-week period is enough to avoid carry
over eﬀect. Blood was collected and processed as above.
The heparinized plasma samples were frozen at −20
◦C
and analyzed by high-performance liquid chromatography
(HPLC). All samples were analyzed within one week after
each experimental phase.
2.4. Analytical Method. Plasma concentrations of lev-
oﬂoxacin were measured using a modiﬁed HPLC method
[25]. Brieﬂy, the HPLC system was performed on Shi-
madzu Liquid Chromatography System (Duisburg, Ger-
many) equipped with an LC9A pump, an automatic sampler
SIL6B, and a UV detector. Class LC 10 software version
1.6 (Shimadzu) was used for data analysis and processing.
Levoﬂoxacin and ciproﬂoxacin (as internal standard, 99.2
pure, 1μg1 0 /μL methanol) were isolated from plasma. The
plasma proteins were removed via methanol precipitation;
200μl plasma were mixed with 400μlm e t h a n o la n dv i g o r -
ously shaken. The precipitated proteins were removed via
centrifugation at 12000 × g for 5min. Subsequently, 20μlo f
the supernatant were injected onto the column.
The HPLC separation was performed using a reversed-
phase C18 column (Discovery, Supelco, 5μm, 4.6mm ×
150mm)withaninjectionvolumeof20μl.Themobilephase
consisted of water:acetonitrile (80 : 20, v/v) with 0.3% of
triethylamine and pH adjusted to 3.3 with phosphoric acid,
using an isocratic form with a ﬂow rate of 1.0 mL /min.
Thedetectorwavelengthwassetat295nm.Theanalyteswere
identiﬁed from the retention times of 97–99% pure reference
standards.
The calibration curves of plasma were prepared with
seven diﬀerent concentrations between 0.01 and 10μg/mL
using blank sheep plasma. A calibration curve was obtained
by plotting the peak height ratio versus the nominal con-
centrations. The equation was calculated by the least-squares
method using linear regression. The limit of quantiﬁcation
(LOQ) based on a signal-to-noise ratio >5w a s0 .04μg/mL
of levoﬂoxacin in supplemented sheep plasma. Under our
experimental conditions, the linearity of the method was
from 0.01 to 10μg/mL of levoﬂoxacin sheep plasma, and
the value of correlation coeﬃcients (r)w a s>0.99. The peak
height ratios of an unknown specimen (peak height of lev-
oﬂoxacin/peak height of internal standard) were compared
with that of the standard.
Theprecisionandaccuracyofthemethodwereevaluated
by repetitive analysis of the plasma samples (n = 12) spiked
with diﬀerent known concentrations of levoﬂoxacin. The
percentage recoveries were determined by comparing the
peak height of blank samples spiked with diﬀerent amounts
of drug and treated as any sample, with the peak height
of the same standards prepared in phosphate buﬀer (n =
6). Intra-assay variations were determined by measuring
six replicates (n = 6) of three standard samples used for
calibrationcurves.Theintra-assayvariationcoeﬃcientswere
<4.3%.Interassayprecisionsweredeterminedbyassayingthe
threestandardsamplesonthreeseparatedays.TheInterassay
variation coeﬃcients were <4.6%. Recovery of levoﬂoxacin
from plasma was found to be 93%.
2.5. In Vitro Plasma Protein Binding. The extent of plasma
protein binding was determined in vitro using ultraﬁltration
[26]; antimicrobial-free plasma from sheep fortiﬁed with
known concentrations of levoﬂoxacin (0.01, 0.16, 0.32,
1.25, 5, and 10μg/mL) was used. One ml of each sample
was placed on a conditioned semipermeable membrane
(Centriﬂow Cones CF-50, Amicon Corp., Lexington, MA,
USA) resting on porous conical polyethylene support on the
top of centrifuge tubes. The tubes were centrifuged at 1500g
for 45–60min. Plasma samples and their corresponding
ultraﬁltrates were assayed by the same method (HPLC) as
described above. The percentage of plasma protein binding
was calculated according to the following equation:
Protein binding%
=
Total concentration −Ultraﬁltrate concentration
Total concentration
×100.
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Figure 1: Mean ± SD plasma concentrations of levoﬂoxacin in
sheep after intravenous () and intramuscular (•) injection of
4mg/kgb.wt.(n = 10).
2.6. Pharmacokinetic Analysis. Pharmacokinetic analysis of
plasma levoﬂoxacin concentration versus time data was
conducted by noncompartmental analysis using WinNonLin
Professional version 4.1 software package (Pharsight Cor-
poration, Mountain View, California). For the intravenous
data, the appropriate pharmacokinetic model was deter-
mined by visual examination of individual concentration-
time curves and by application of Akaike’s Information
Criterion (AIC) [27]. The plasma concentration-time rela-
tionship was best estimated as a two-compartment open
model:
Cp = Ae−αt +Be−βt,( 2 )
whereCp is the concentration of drug in the plasma at time t,
A and B are the zero-time drug intercepts of the distribution
and elimination phase expressed as μg/mL, α and β are the
distribution and elimination rate constants expressed in
units of reciprocal time (h−1), and e is the natural logarithm
base. The distribution and elimination half-lives (t1/2α and
t1/2β) were calculated according to standard equations [28],
while the volume of distribution at steady state (V(d(ss)))a n d
the mean residence time (MRT) were calculated according to
the following equations (V(d(ss)) = ClB × MRT and MRT =
AUMC/AUC), respectively.
Following IM administration of levoﬂoxacin, plasma
concentrations data were analyzed by both compartmental
and noncompartmental methods based on the statistical
moment theory [28]. The terminal elimination half-life
(t1/2el) and absorption half-life (t1/2(a) ) were calculated as
ln2/kel or ln2/ka,r e s p e c t i v e l y ,w h e r ekel and kab are the elim-
ination and absorption rate constant, respectively. The areas
under the concentration-time curves (AUC) were calculated
by the trapezoidal rule and further extrapolated to inﬁnity
by dividing the last experimental plasma concentration by
the terminal slope (β). The mean residence time (MRT) was
calculated as AUMC/AUC, where AUMC is the area under
the ﬁrst moment curve, each individual curve of levoﬂoxacin
over time was analyzed to determine the peak concentration
Cmax (extrapolated from the curve), and the time to peak
concentration Tmax was read from the data. The systemic
clearance was calculated as Cl = Dose/AUC. The absolute
bioavailability (F%) was calculated as (AUCIM/AUCIV) ×
100. In case of extravascular administration, the volume
of distribution at steady state (V(d(ss))) and the systemic
clearance (ClB) were calculated according to the following
equations (V(d(ss)) = Vd/F) and ClB = ClB/F, respectively.
Pharmacodynamic eﬃcacy of levoﬂoxacin was deter-
mined by calculating the Cmax/MIC and AUC24/MIC ratios
followingIMadministrationsusingtherespectivemeanMIC
value for susceptible Klebsiella spp. (0.06μg/mL), Shigella
spp.(0.06μg/mL),Salmonellaspp.(0.12μg/mL),Proteusspp.
(0.06μg/mL), and Acinetobacter spp. (0.12μg/mL) according
to Marshall and Jones [29]; these values were derived
from those determined in the studies involving antibacterial
activity of levoﬂoxacin against strains isolated from human
beings.
2.7. Statistical Analysis. The statistical analysis was per-
formed using the SPSS 17.1 software package (SAS, Cary,
NC, USA). Results are presented as arithmetic mean ± SD.
The nonparametric Wilcoxon test was used to compare the
parameters obtained after intravenous and intramuscular
administration. Means were considered signiﬁcantly diﬀer-
ent at P<. 05.
3. Results
Clinical examination of all animals before and after each
trial did not reveal any abnormalities. No adverse reactions
were observed after the single-dose IV or IM administration
of levoﬂoxacin in the animals studied. Akaike’s Information
Criterion test indicated that a two-compartment model best
represented the plasma concentration versus time data after
IV administration of levoﬂoxacin in sheep.
The mean plasma concentration-time proﬁles of lev-
oﬂoxacin following single IV and IM administrations of
4mg/kg b.wt are presented graphically in Figure 1.M e a n
± SD values of pharmacokinetic parameters estimated from
the curve ﬁtting are shown in Table 1. In vitro plasma
protein binding of levoﬂoxacin was 23.74%. Following
intramuscular administrations of levoﬂoxacin using MIC ≤
0.12μg/mL, the Cmax/MIC90 ratio was 25.83-fold, and the
AUC0−24/MIC90 ratio was 160.42h.
4. Discussion
Plasma levoﬂoxacin disposition curves after IV injection
were best ﬁt to an open bicompartmental model in all the
animals, which is in accordance with the results reported for
calves and lactating goats, respectively, [20, 21].
The V(d(ss)) is a clearance-independent volume of dis-
tribution that is used to calculate the drug amount in the
body under equilibrium conditions [30]. Fluoroquinolones
are lipid-soluble drugs that have a large volume of dis-
tribution [31]. The V(d(ss)) for levoﬂoxacin was 0.86l/kg
in sheep indicating a relatively wide distribution after4 Veterinary Medicine International
Table 1: Mean ± SD plasma pharmacokinetic parameters of levoﬂoxacin (μg/mL) in sheep (n = 10) following IV and IM administration at
a dose rate of 4mg/kg b.w.
Parameters Unit IV IM
α h
−1 2.19 ±0.17 —
ka h
−1 —1 .39 ±0.15
t1/2α h0 .33 ±0.12 —
t1/2(a) h— 0 .51 ±0.11
β h
−1 0.19 ±0.09 —
kel h
−1 —0 .21 ±0.04
t1/2β h3 .29 ±0.23 —
t1/2el h— 3 .58 ±0.30
V(d(ss)) l/kg 0.86 ±0.23 1.02 ±0.18
ClB L/h.kg 0.20 ±0.05 0.19 ±0.03
AUC μg.h/mL 21.61 ±1.24 20.24 ±1.31
∗
MRT h 4.26 ±0.94 5.33 ±1.05
∗
Cmax μg/mL 12.17 ±1.73 3.10 ±0.35
Tmax h— 1 .64 ±0.29
F %— 9 1 .35 ±6.81
β (kel): elimination rate constant; α (ka): distribution (absorption) rate constant; t1/2α: distribution half-life; t1/2(a): absorption half-life; t1/2β (t1/2el):
elimination half-life; V(d(ss)): volume of distribution; ClB: total body clearance; AUC: area under the curve from zero to inﬁnity by the trapezoidal integral;
MRT: mean residence time; Cmax: maximum plasma concentration; Tmax: time to peak concentration; F(%): bioavailability; for IM, (V(d(ss)) = Vd/F)a n d
ClB = ClB/F
∗P <. 05.
IV administration and it was slightly diﬀering from that
reported for levoﬂoxacin in lactating goats 0.73l/kg [21]
and moxiﬂoxacin in lactating goats (0.79l/kg) [32]. The
discrepancies between values calculated for pharmacokinetic
parameters may be attributed to the animal species, the drug
formulation employed, the age, size or sex of the animals, to
diﬀerences in fatty tissue deposits between animal species or
breeds, or even to interindividual variations and also due to
the method of analysis of the drug [33].
The clearance of levoﬂoxacin in sheep was 0.2L/h.kg
similar to those values reported in calves and lactating goats
0.19 and 0.18L/h.kg [20, 21], respectively.
The elimination half-life of levoﬂoxacin following IV
administrationwas3.29h.Thisvalueisclosetothatreported
for levoﬂoxacin in lactating goats 2.95h [21] and longer than
t h a tr e p o r t e di nc a l v e s[ 20] 1.61h, and shorter than that
reported in rabbits 7.50h [18].
Following intramuscular injection, the present data
were best represented by a one-compartment model and
the estimated Cmax (3.10μg/mL) was similar to that data
reported in calves and lactating goats (3.07 and 3.16μg/mL)
[19, 21], respectively.
The time to reach the maximum concentration of
levoﬂoxacin in sheep (Tmax = 1.64h) was longer than that
recorded levoﬂoxacin in calves (1.00h) [19] and shorter
than that reported in lactating goats 1.76h [21]. The
absorption process of levoﬂoxacin was moderately fast as
showed by the absorption rate constant (ka)1 .39h
−1 , short
absorption half-life (t1/2(a))0 .51h, and conﬁrmed by the
short Tmax (1.64h). The overall MRT was longer for IM
administration compared with that for IV injection, with an
estimated time of 5.33h. This was expected as the MRT after
IMinjectiondependsonboththedispositionandabsorption
rates. The MRT of levoﬂoxacin was similar to that recorded
for calves and lactating goats (5.57 and 5.24h) [19, 21],
respectively.
The elimination half-life value was 3.58h after IM
administration, similar to that recorded for calves and
lactating goats (3.67 and 3.64h) [19, 21], respectively.
The systemic bioavailability of levoﬂoxacin in sheep after
IM administration was 91.35%, and the absorption process
was rapid with absorption half-life (t1/2(a))0 .51h. This value
indicates the excellent absorption of the drug from that
injection site. This value was similar to values reported for
lev oﬂo xacininlactatinggoats[21]andmoxiﬂoxacininsheep
[34] and that reported value was eﬀectively higher than that
reported for calves 56.6% [19].
Proteinbindinghaslongbeenconsideredoneofthemost
important physicochemical characteristics of drugs, playing
a potential role in distribution, excretion, and therapeutic
eﬀectiveness as a low protein binding generally enables
a rapid and extensive distribution into the intracellular
and extracellular space [35]. In this study, the in vitro
plasma protein binding experiment showed that levoﬂoxacin
displayed a low level of binding to plasma proteins (approx-
imately 23.74%) to sheep plasma. The results of in vitro
protein binding may diﬀer substantially depending on the
methodology and experimental conditions [36]. The lowVeterinary Medicine International 5
protein binding of levoﬂoxacin in sheep plasma proteins is in
agreementwithpreviouslyreportedvalueof22%inlactating
goats [21], 24% in human [12] and 25% in rabbits [18].
Nevertheless, it was relatively lower to that reported (17%)
in calves [19].
It has been established that for concentration-dependant
ﬂuoroquinolones, the AUC0−24/MIC90 ratio is the most
important eﬃcacy predictor, with the rate of clinical cure
being greater than 80% when this ratio is higher than
100–125 [37]. A second predictor of eﬃcacy for con-
centration dependent antibiotic is the ratio Cmax/MIC90,
considering that values ≥10 would lead to better clinical
results [38]. High Cmax/MIC90 ratios have been associated
with a lower incidence resistance development [39]. It is
suggested that the critical break points determining the
eﬃcacy of ﬂuoroquinolones are Cmax/MIC90 ≥8–10, and
AUC0−24/MIC90 ≥100 [38, 39]. The MIC of levoﬂoxacin has
not yet been determined for bacteria isolated from sheep. To
cover most of the susceptible organisms, in this discussion,
the MIC90 of 0.12μg/mL of levoﬂoxacin has been taken into
consideration [29]. Based on this data, a dosage of 4mg/kg
levoﬂoxacin IM in sheep would result in a Cmax/MIC90 ratio
of 25.83-fold, which exceeds the recommended ratio of 10.
The second surrogate marker AUC24/MIC90 was 160.42h.
Based on the calculated Cmax/MIC90 and AUC0−24/MIC90,a
dosage of 4mg/kg b.wt. is recommended to treat infections
caused by bacteria with MIC ≤ 0.12μg/mL.
It can be concluded that levoﬂoxacin administered intra-
venously or intramuscularly in the applied dosing sched-
ule is eﬃcacious against bacteria with MIC≤0.12μg/mL.
Consequently, levoﬂoxacin could be useful in the treatment
of systemic infections in sheep after speciﬁc assessment of
susceptible micro-organisms, also, when approved therapy
fails, levoﬂoxacin may be used in some countries for therapy
of food animals, however, that is not true in the US. Only
enroﬂoxacin is approved for beef cattle and cannot be used
extralabel.
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